-
Mashup Score: 5Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma - 25 day(s) ago
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations - 3 month(s) ago
Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations - 3 month(s) ago
Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Podcasts | Clinical Oncology News & Insights | OncLive - 4 month(s) ago
The podcast section includes OncLive on Air® podcast episodes, which focus on clinical oncology news and expert insights in cancer care. Listen on OncLive.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection - 6 month(s) ago
Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
In this episode of #OncLiveOnAir, Dr Keshava, of @UCIrvine, discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses. https://t.co/C7JLCJrMvf https://t.co/PYSpXQSmFk
-
-
Mashup Score: 0Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection - 6 month(s) ago
Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
In this episode of #OncLiveOnAir, Dr Keshava, of @UCIrvine, discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses. https://t.co/C7JLCJrMvf https://t.co/PYSpXQSmFk
-
-
Mashup Score: 0Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma - 7 month(s) ago
Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma - 7 month(s) ago
Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In this episode of #OncLiveOnAir, Drs Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related AEs. https://t.co/54GhablYzT https://t.co/Vg53yUH7GM